<DOC>
	<DOCNO>NCT00230399</DOCNO>
	<brief_summary>This study examine new combination drug : celecoxib , capecitabine irinotecan , treatment metastatic colorectal cancer . Capecitabine irinotecan , individually , approve Food Drug Administration ( FDA ) use colorectal cancer . The combination two drug experimental ( approved FDA standard treatment ) , widely use treatment option preliminary study show treatment combination capecitabine irinotecan positive effect metastatic colorectal cancer . Likewise , previous research animal show celecoxib , drug approve arthritis therapy , also activity tumor type may improve anti-cancer activity combination capecitabine irinotecan .</brief_summary>
	<brief_title>Combination Chemotherapy Treatments Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Patient must histologically prove adenocarcinoma colon rectum metastases local recurrence . 2 . Patients must least one measurable lesion accord RECIST criterion . Bone metastases , ascites pleural effusion measurable . 3 . Minimum indicator lesion size follow : Greater equal 20 mm measure conventional CT Greater equal 10 mm measure spiral technique 4 . Prior use celecoxib treatment nonmalignant disorder allow . 5 . Patients must performance status 0,1 , 2 Southwest Oncology Group criterion . 6 . Patients must calculate creatinine clearance great 50 ml/min . 7 . Patients must absolute neutrophil count great equal 1500/ml , platelet count great equal 100,000/ml , total serum bilirubin equal less institution 's upper limit normal range . 8 . Patients must recover effect surgery . 9 . Evaluable disease must present outside radiation field . At least 3 week must elapse discontinuation radiation therapy . 10 . Patients must provide sign consent participate study . 1 . Patients proven history peptic ulcer disease gastroesophageal reflux . 2 . Patients experience asthma , urticaria , allergictype reaction take aspirin nonsteroidal antiinflammatory drug . 3 . Patients receive prior chemotherapy colorectal cancer ( include capecitabine irinotecan ) except patient relapse 6 month completion adjuvant chemotherapy . 4 . History malignancy , except cancer treat curative intent patient without evidence active disease . 5 . Unresolved bacterial infection require treatment antibiotic . 6 . Pregnant lactate woman may participate study . Women/men reproductive age group may participate unless agree use effective method contraception . 7 . Patients allergy study drug sulfa drug . 8 . Patients know HIV1 virus infection undetermined effect chemotherapy regimen patient HIV1 potential serious interaction antiHIV medication . 9 . Gilbert 's disease . 10 . Lack physical integrity upper gastrointestinal tract . Inability swallow tablet malabsorption syndrome . 11 . Other serious concurrent infection 12 . Clinically significant cardiac disease well control medication ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia ) myocardial infarction within last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>